文献速递免疫规划卫生政策与健康促进

意大利80岁及以上人群接种第二剂COVID-19 mRNA疫苗加强针后至四个月的相对有效性:一项回顾性匹配队列研究

Relative effectiveness of a 2nd booster dose of COVID-19 mRNA vaccine up to four months post administration in individuals aged 80 years or more in Italy: A retrospective matched cohort study.
PubMed 文献 · Vaccine · 2022-11-14

本研究基于意大利国家疫苗接种登记和COVID-19监测系统链接数据,在2022年4月11日至8月6日期间每日按人口学和临床特征1:1匹配接种第二剂加强针与至少120天前接种第一剂加强针的≥80岁人群,共831,555对匹配。结果显示,第二剂加强针接种后14-118天对SARS-CoV-2感染有中等保护效果(相对疫苗有效性14.3%,95%CI 2.2-20.2),对重症COVID-19保护更高(34.0%,95%CI 23.4-42.7),但随时间下降。

要点

  • 第二剂mRNA加强针接种后14-118天对SARS-CoV-2感染的相对疫苗有效性为14.3%(95%CI 2.2-20.2)。
  • 对重症COVID-19的相对疫苗有效性为34.0%(95%CI 23.4-42.7),14-28天为43.2%,56-118天降至27.2%。
  • 对感染的相对疫苗有效性从14-28天的28.5%降至56-118天的7.6%(95%CI -14.1至18.3)。

核心结论

  • 第二剂mRNA加强针接种后2-4个月对SARS-CoV-2感染的相对疫苗有效性大幅降低,但对重症COVID-19的相对疫苗有效性仍约为30%,即使在Omicron BA.5亚变异株流行期间。
  • 对于至少四个月前接种第二剂加强针的老年人,第三剂加强针的成本效益应仔细评估。

研究设计与样本

  • 回顾性匹配队列研究,链接意大利国家疫苗接种登记和COVID-19监测系统数据。
  • 在2022年4月11日至8月6日期间每日按人口学和临床特征1:1匹配接种第二剂加强针者与至少120天前接种第一剂加强针者,共831,555对匹配。
  • 使用Kaplan-Meier方法比较两组SARS-CoV-2感染和重症COVID-19(住院或死亡)风险,计算相对疫苗有效性(RVE)为(1-风险比)×100。

主要发现

  • 第二剂mRNA加强针接种后14-118天,对SARS-CoV-2感染的RVE为14.3%(95%CI 2.2-20.2)。
  • 对感染的RVE从14-28天的28.5%(95%CI 24.7-32.1)降至56-118天的7.6%(95%CI -14.1至18.3)。
  • 对重症COVID-19的RVE为34.0%(95%CI 23.4-42.7),从14-28天的43.2%(95%CI 30.6-54.9)降至56-118天的27.2%(95%CI 8.3-42.9)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Several countries started a 2nd booster COVID-19 vaccination campaign targeting the elderly population, but evidence around its effectiveness is still scarce. This study aims to estimate the relative effectiveness of a 2nd booster dose of COVID-19 mRNA vaccine in the population aged ≥ 80 years in Italy, during predominant circulation of the Omicron BA.2 and BA.5 subvariants. We linked routine data from the national vaccination registry and the COVID-19 surveillance system. On each day between 11 April and 6 August 2022, we matched 1:1, according to several demographic and clinical characteristics, individuals who received the 2nd booster vaccine dose with individuals who received the 1st booster vaccine dose at least 120 days earlier. We used the Kaplan-Meier method to compare the risks of SARS-CoV-2 infection and severe COVID-19 (hospitalisation or death) between the two groups, calculating the relative vaccine effectiveness (RVE) as (1 - risk ratio)X100. Based on the analysis of 831,555 matched pairs, we found that a 2nd booster dose of mRNA vaccine, 14-118 days post administration, was moderately effective in preventing SARS-CoV-2 infection compared to a 1st booster dose administered at least 120 days earlier [14.3 %, 95 % confidence interval (CI): 2.2-20.2]. RVE decreased from 28.5 % (95 % CI: 24.7-32.1) in the time-interval 14-28 days to 7.6 % (95 % CI: -14.1 to 18.3) in the time-interval 56-118 days. However, RVE against severe COVID-19 was higher (34.0 %, 95 % CI: 23.4-42.7), decreasing from 43.2 % (95 % CI: 30.6-54.9) to 27.2 % (95 % CI: 8.3-42.9) over the same time span. Although RVE against SARS-CoV-2 infection was much reduced 2-4 months after a 2nd booster dose, RVE against severe COVID-19 was about 30 %, even during prevalent circulation of the Omicron BA.5 subvariant. The cost-benefit of a 3rd booster dose for the elderly people who received the 2nd booster dose at least four months earlier should be carefully evaluated.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Fabiani M, Mateo-Urdiales A, Sacco C, et al. Relative effectiveness of a 2nd booster dose of COVID-19 mRNA vaccine up to four months post administration in individuals aged 80 years or more in Italy: A retrospective matched cohort study. Vaccine. 2022. PMID: 36400660. doi:10.1016/j.vaccine.2022.11.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。